5results about How to "Effective targeting" patented technology

This invention relates to the field of biomedical technology and provides a controllable cryogenic treatment mesenchymal stem cell preparation, its preparation method, and its application. The method includes the following steps: cell preparation and cryopreservation equilibration: digestion and collection; cryopreservation equilibration; removal of cryoprotectant and washing: centrifugation to remove cryopreservation solution; PBS washing; cryogenic incubation: resuspending the final cell pellet after multiple washes in pre-cooled PBS; incubating the cell suspension at 4±0.5℃ for 72 hours±10 minutes; after incubation, removing the cell suspension from the 4℃ environment, centrifuging, and resuspending in PBS. This invention yields a ready-to-use, easily stored and transported, and functionally enhanced RT-MSCs preparation. Although the cells in this preparation have lost their proliferative and metabolic activity, they still retain the complete therapeutic functions of MSCs, such as immunomodulation, anti-fibrosis, and angiogenesis promotion.

This invention discloses an extracellular vesicle derived from Sophora flavescens, its preparation method, and its application. It belongs to the field of biomedical technology. The extracellular vesicles derived from Sophora flavescens are obtained by isolating extracellular vesicles (SF-EVs) from the roots of Sophora flavescens. These vesicles have a particle size of 100-200 nm and contain proteins, lipids, high abundance of miR6300, and various alkaloids. This invention also provides a method for preparing the extracellular vesicles and further provides their application in the preparation of drugs for treating metabolic-associated steatohepatitis (MASH). In vitro and in vivo experiments have demonstrated that SF-EVs can significantly improve lipid accumulation, inflammatory response, and oxidative stress in MASH, with an overall therapeutic effect superior to an equivalent dose of total alkaloids from Sophora flavescens. Through protein / RNA knockout, transcriptome sequencing, and mechanism verification, miR6300 was found to be a key effector of SF-EVs in its anti-MASH effect, and it exerts a synergistic therapeutic effect by dually targeting CYP2B6 (improving lipid metabolism) and CXCL10 (inhibiting inflammation).

This invention relates to the field of pancreatic cancer drug technology, and discloses a drug delivery nanomaterial encapsulating a cell membrane and its preparation method. The preparation method includes: dissolving PLGA, a sonosensitive agent IR780, and an immunoadjuvant R837 in a mixed organic solvent of dichloromethane and ethanol to form an oil phase; adding the oil phase to a PVA aqueous solution, ultrasonically emulsifying to form an emulsion, then adding an isopropanol aqueous solution, stirring and solidifying, and removing the organic solvent to obtain drug-loaded nanoparticles IR780 / R837@PLGA; finally, mixing the drug-loaded nanoparticles with the cell membrane of Panc02 pancreatic cancer cells in DEPC water and ultrasonically treating to obtain the drug delivery nanomaterial M-IR780 / R837@PLGA encapsulated by the cell membrane of Panc02 pancreatic cancer cells. This material can effectively target pancreatic tumors and prolong their in vivo circulation time, thereby enhancing the targeted therapy and immunotherapy effects of pancreatic cancer.

The application discloses a nano material for targeting and driving resuscitation of dying cells, and a preparation method and application thereof. The nano material is a nano platelet vesicle with phosphatidylserine exposed to the outer layer of the membrane after nanoization and centrifugal treatment. The material is obtained by separating and enriching platelets from peripheral blood, then nanoizing the platelets, and then inducing the phosphatidylserine on the platelet membrane to evert through high-speed centrifugation. The material is used for preparing a medicine for promoting tissue repair, and the medicine promotes resuscitation of dying cells by targeting the dying cells and enhancing the membrane repair capacity of the dying cells, so as to promote tissue repair, including repair of orthopedic, muscle, skin, spinal cord or visceral tissue, especially repair of diabetic foot, skin avulsion injury, ischemic skin flap or spinal cord injury. The resuscitation of dying cells is promoted successfully without intervention of lysis programmed cell death initiation, so that the problems of off-target effect and treatment paradox existing in current mainstream small molecule inhibitor strategy are effectively solved.

The application provides an ultrasonic device and a control method for real-time modulation of ultrasonic parameters based on pain monitoring, comprising a controller, a treatment head and a signal acquisition assembly, the treatment head comprising a shell and an ultrasonic treatment transducer, the side of the shell facing the patient being provided with an acoustic window for emitting treatment ultrasonic waves to the skin surface, the controller calculating a pain index of the patient based on physiological signals collected by the signal acquisition assembly, and non-uniformly modulating the main pulse period parameters and multi-dimensional sub-pulse distribution parameters of the ultrasonic treatment transducer through an algorithm. The ultrasonic device can objectively evaluate the pain state of the patient by introducing multi-dimensional feedback feature information and evaluation mechanism, and can predict and adjust the patient's characteristics in advance. Through the dynamic change of pulse energy modulation, the specific nerve fibers can be accurately targeted, the analgesic effect is better, the side effects are significantly reduced, and the expected treatment effect is achieved.